Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.
about
Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils.Inhibiting TRK Proteins in Clinical Cancer Therapy.
P2860
Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Merestinib blocks Mnk kinase a ...... effects in vitro and in vivo.
@en
Merestinib blocks Mnk kinase a ...... effects in vitro and in vivo.
@nl
type
label
Merestinib blocks Mnk kinase a ...... effects in vitro and in vivo.
@en
Merestinib blocks Mnk kinase a ...... effects in vitro and in vivo.
@nl
prefLabel
Merestinib blocks Mnk kinase a ...... effects in vitro and in vivo.
@en
Merestinib blocks Mnk kinase a ...... effects in vitro and in vivo.
@nl
P2093
P2860
P1433
P1476
Merestinib blocks Mnk kinase a ...... effects in vitro and in vivo.
@en
P2093
Barbara Kroczynska
Diana Saleiro
Elspeth M Beauchamp
Ewa M Kosciuczuk
Francis J Giles
Frank Eckerdt
Gavin T Blyth
Jessica K Altman
Leonidas C Platanias
P2860
P304
P356
10.1182/BLOOD-2016-02-698704
P407
P577
2016-06-15T00:00:00Z